A Clinical Study Using FAPI-PET Imaging to Assess the Postoperative Effects of TAVI in Patients With Aortic Stenosis
Summary
This study will include patients with severe degenerative aortic stenosis (AS) who meet the inclusion criteria and voluntarily participate (planned to undergo TAVI), as well as patients with aortic stenosis who have not undergone valve replacement (control group). All enrolled patients will undergo a \^18F-FAPI-1801 PET/CT scan at baseline (before or at the time of TAVI) and 6 months postoperatively to quantitatively evaluate myocardial fibroblast activation and structural remodeling indicators, and to follow up on changes in clinical cardiac function. Patients with aortic stenosis receiving only medical therapy will be set as the control group for comparative analysis, to assess the impact of relieving aortic stenosis on the reduction of myocardial fibrosis activity, myocardial remodeling, and reversal of cardiac function.
Timeline
- Start
- 2025-12-19
- Primary completion
- 2026-12-30
- Completion
- 2027-05-30
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Background | Bisoprolol | Other / unclassified | — | — |
| Background | Carvedilol | Other / unclassified | — | — |
| Background | Dapagliflozin | Small molecule | — | — |
| Background | Empagliflozin | Small molecule | — | — |
| Background | Eplerenone | Unknown | — | — |
| Background | Furosemide | Other / unclassified | — | — |
| Background | Metoprolol | Other / unclassified | — | — |
| Background | Spironolactone | Small molecule | — | — |
| Background | Torasemide | Unknown | — | — |
| Background | Vericiguat | Other / unclassified | — | — |
| Background | sacubitril/valsartan | Unknown | — | — |